Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
CDMO acquires Syntagon, maker of novel APIs and excipients
May 10, 2018
By: Tim Wright
Editor-in-Chief, Contract Pharma
The contract development and manufacturing organization (CDMO) Ardena, has acquired Syntagon, a contract manufacturer of novel active pharmaceutical ingredients (APIs) and excipients. The acquisition, which is the CDMO’s first outside the Benelux region, expands its drug substance manufacturing capacity and means that bigger batch sizes up to 100 kg can now be handled by Ardena. Syntagon also adds specialist expertise in GMP chromatographic purification processes to the group. The announcement follows Ardena’s acquisition of ChemConnection in March 2018 and is part of its strategy to form a leading integrated drug development company and reach the €35 million sales mark this year. “At Ardena, it is our goal to become a one source contractor by offering an integrated set of services to meet all chemical, pharmaceutical and (bio)analytical needs that arise in the clinical supply chain from lab to patient. This is the driver of our M&A strategy,” said Harry Christiaens, chief executive officer, Ardena. “By adding the ChemConnection and Syntagon capabilities to our group, we can now offer specialist technology expertise in drug substance manufacturing.” Established in 1999, Syntagon has sites in Sweden and Latvia and employs 30 people. This latest acquisition brings the total number of Ardena facilities to six, including its headquarters in Ghent, Belgium and three sites in the Netherlands (Oss, Amsterdam and Assen). Mr. Christiaens said, “The Syntagon acquisition gives us a presence in Scandinavia, where we are well positioned to capitalize on the emerging biotech segment and broader pharmaceutical market. With support from our financial investor Mentha Capital, we will continue to focus on both organic growth and acquisition opportunities on our path to create an internationally recognized drug development company.” Michael Lofthagen, chief executive officer, Syntagon, said, “Our customers can now benefit from a more integrated service offering, which will ultimately streamline the progress of products through clinical development. We are looking forward to leveraging the synergies across the Ardena group to deliver the best possible offering to the market.” Ardena was formed in 2017, following the merging of three companies with complementary capabilities: Pharmavize in Belgium, and Crystallics and Analytical Biochemical Laboratory (ABL) in the Netherlands. With the acquisitions of ChemConnection and Syntagon in 2018, Ardena now employs more than 225 scientists.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !